Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 201–300 of 1,008
ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity
Colicelli, J. (2010) · Science Signaling · doi:10.1126/scisignal.3139re6 · Cited by 347
“Drug resistance is typically a consequence of mutations in the BCR-ABL1 kinase domain (229, 230), but may also result from mutations in the SH3 and SH2 domains (231, 232) or BCR-ABL1 amplification (229).”
BackgroundHochhaus, A., Baccarani, M., Deininger, M., Apperley, J. F., Lipton, J. H., Goldberg, S. L., Corm, S., Shah, N. P., Cervantes, F., Silver, R. T., et al. (2008) · Leukemia · doi:10.1038/leu.2008.84 · Cited by 352
“This suggests that dasatinib may overcome other possible mechanisms of imatinib resistance, for example, BCR–ABL gene amplification, P-glycoprotein efflux pump overexpression and SRC family kinase dysregulation”
BackgroundPhiladelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics
Kurzrock, R., Kantarjian, H. M., Druker, B. J., & Talpaz, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00010 · Cited by 345
Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
Cowan-Jacob, S. W., Fendrich, G., Manley, P. W., Jahnke, W., Fabbro, D., Liebetanz, J., & Meyer, T. (2005) · Structure · doi:10.1016/j.str.2005.03.012 · Cited by 335
Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues
Lundby, A., Secher, A., Lage, K., Nordsborg, N. B., Dmytriyev, A., Lundby, C., & Olsen, J. V. (2012) · Nature Communications · doi:10.1038/ncomms1871 · Cited by 343
“7) and bcr-abl 8 are often the oncogenic drivers of cell transformation.”
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00179-1 · Cited by 335
Chen, L. L., Trent, J. C., Wu, E. F., Fuller, G. N., Ramdas, L., Zhang, W., Raymond, A. K., Prieto, V. G., Oyedeji, C. O., Hunt, K. K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0085 · Cited by 339
“Kinase domain mutations in ABL in leukemia have almost always been associated with imatinib resistance (18-20).”
BackgroundStrategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
“This has been shown in a subset of relapsed CML patients, whose levels of the Bcr–Abl fusion protein were elevated as a result of gene amplificatio”
BackgroundImatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Hochhaus, A., & La Rosée, P. (2004) · Leukemia · doi:10.1038/sj.leu.2403426 · Cited by 336
Dual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Targeting HSP90 for cancer therapy
Mahalingam, D., Swords, R., Carew, J. S., Nawrocki, S. T., Bhalla, K., & Giles, F. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605066 · Cited by 317
“However, patients can develop imatinib resistance associated with BCR-ABL gene amplification and/or kinase domain mutations, which abrogate imatinib-binding or function (Gorre et al, 2001).”
BackgroundEvolution in Health and Disease
(2007) · doi:10.1093/acprof:oso/9780199207466.001.0001 · Cited by 320
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
Lennartsson, J., Jelacic, T., Linnekin, D., & Shivakrupa, R. (2005) · STEM CELLS · doi:10.1634/stemcells.2004-0117 · Cited by 303
Resistance to chemotherapy: new treatments and novel insights into an old problem
Raguz, S., & Yagüe, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604510 · Cited by 312
“Unfortunately, not long after its initial use, resistance to imatinib was demonstrated in CML patients (Gorre et al, 2001).”
Antimyeloma activity of heat shock protein-90 inhibition
Mitsiades, C. S. (2005) · Blood · doi:10.1182/blood-2005-03-1158 · Cited by 319
An, X., Tiwari, A. K., Sun, Y., Ding, P.-R., Ashby, C. R., & Chen, Z.-S. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.016 · Cited by 309
“[22], who found that 6 of 9 advanced h 34 (2010) 1255–1268”
BackgroundInfluentialThe New Era in Cancer Research
Varmus, H. (2006) · Science · doi:10.1126/science.1126758 · Cited by 308
Mapping normal and cancer cell signalling networks: towards single-cell proteomics
Irish, J. M., Kotecha, N., & Nolan, G. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1804 · Cited by 316
Jørgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C., & Holyoake, T. L. (2007) · Blood · doi:10.1182/blood-2006-11-057521 · Cited by 306
Corbin, A. S., Rosée, P. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 258
Illmer, T., Schaich, M., Platzbecker, U., Freiberg-Richter, J., Oelschlägel, U., von Bonin, M., Pursche, S., Bergemann, T., Ehninger, G., & Schleyer, E. (2004) · Leukemia · doi:10.1038/sj.leu.2403257 · Cited by 307
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
“In addition, the imatinib experience has highlighted the problem of drug resistanc”
BackgroundA Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., Cole, P. A., & Kuriyan, J. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040144 · Cited by 309
“Clinical resistance to imatinib therapy is a growing problem in the treatment of chronic myeloid leukemia [46].”
BackgroundPushing the limits of targeted therapy in chronic myeloid leukaemia
O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3317 · Cited by 304
O'Farrell, A.-M., Foran, J. M., Fiedler, W., Serve, H. L., Paquette, R. L., Cooper, M. A., Yuen, H. A., Louie, S. G., Kim, H., Nicholas, S., et al. (2003) · PubMed · Cited by 332
Self-citationMechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
“In some cases, amplification of the oncogenic protein kinase gene can confer resistanc”
BackgroundImplementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
“Secondary mutations in BCR–ABL, which render imatinib ineffective (Gorre et al., 2001), can only explain drug resistance to imatinib in 30% of the cases.”
BackgroundBattling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 289
“A survival-threatening mutation in the BCR-ABL kinase drug binding site is a well-known risk factor that causes resistance to the drug Gleevec [94].”
BackgroundBCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Koptyra, M., Falinski, R., Nowicki, M. O., Stoklosa, T., Majsterek, I., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2006) · Blood · doi:10.1182/blood-2005-07-2815 · Cited by 298
Flying under the radar: the new wave of BCR–ABL inhibitors
Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2324 · Cited by 305
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Self-citationKantarjian, H. M., Talpaz, M., O'Brien, S., Giles, F., Garcia-Manero, G., Faderl, S., Thomas, D., Shan, J., Rios, M. B., & Cortes, J. (2003) · Blood · doi:10.1182/blood-2002-05-1451 · Cited by 306
“Loss of CG CR or CG PR Ph exceeding 90% 19 (14-26) 3 NA 0 0 1 Ph 35% to 90% 21 (12-27) 6 NA 3 2 0 Loss of minor CG response to 100% Ph 18 (15-25) 4 NA 1 1* 0 1 1*”
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Cowan-Jacob, S. W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., Rheinberger, P., Centeleghe, M., Fabbro, D., & Manley, P. W. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906047287 · Cited by 296
“Additional structural biology studies have established the mechanisms whereby mutant forms of the oncoprotein were resistant to imatinib ( Gorre et al., 2001, Cowan-Jacob et al., 2004).”
Aichberger, K. J., Herndlhofer, S., Schernthaner, G., Schillinger, M., Mitterbauer‐Hohendanner, G., Sillaber, C., & Valent, P. (2011) · American Journal of Hematology · doi:10.1002/ajh.22037 · Cited by 296
“However, despite impressive long-term results in chronic phase (CP) CML, resistance against imatinib has been described, which is often associated with BCR/ABL mutations [5,6].”
BackgroundWillis, S. G., Lange, T., Demehri, S., Otto, S., Crossman, L., Niederwieser, D., Stoffregen, E. P., McWeeney, S., Kovacs, I., Park, B., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1036 · Cited by 302
“progressive disease 48 BC HU, IFN 47,XX, 8,t(9; 22)(q34;11) [16],46,XX,t(9; 22)[4] T315I 45.”
Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307203101 · Cited by 299
Zhou, T., Commodore, L., Huang, W., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01054.x · Cited by 287
“However, many patients eventually develop resistance, usually associated with mutations in the ABL kinase domain that either directly or indirectly affect the binding affinity of imatinib to ABL (9,10).”
BackgroundCortes, J., Jabbour, E., Kantarjian, H., Yin, C. C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 296
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
Powers, M. V., & Workman, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01324 · Cited by 285
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl–Crk pathway
Noren, N. K., Foos, G., Hauser, C. A., & Pasquale, E. B. (2006) · Nature Cell Biology · doi:10.1038/ncb1438 · Cited by 288
“To confirm that Abl family kinases are the targets of Gleevec downstream of EphB4, we used a naturally occurring Gleevec-insensitive Abl mutant (Abl TI ), that was identified in chronic myelogenous leukemia patients that acquired resistance to Gleeve”
BackgroundNelson, E. A., Walker, S. R., Weisberg, E., Bar-Natan, M., Barrett, R., Gashin, L. B., Terrell, S., Klitgaard, J. L., Santo, L., Addorio, M. R., et al. (2011) · Blood · doi:10.1182/blood-2009-11-255232 · Cited by 280
Combined Surgical and Molecular Therapy: The Gastrointestinal Stromal Tumor Model
Gold, J. S., & DeMatteo, R. P. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000218080.94145.cf · Cited by 288
“This is concordant with the finding that in chronic myeloid leukemia treated with imatinib, second site mutation in BCR-ABL is the primary mechanism of resistance.(53,54) Often, novel mutations arise that have not been found in imatinib-naive GIST.”
ResultJabbour, E., Kantarjian, H., Ravandi, F., Thomas, D., Huang, X., Faderl, S., Pemmaraju, N., Daver, N., Garcia-Manero, G., Sasaki, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00207-7 · Cited by 281
Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux
Dai, H., Marbach, P., Lemaire, M., Hayes, M., & Elmquist, W. F. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045260 · Cited by 273
“It has also been established that resistance to STI-571 has occurred in some patients due to a point mutation in the ATP-binding site of the enzyme or multiplication of the BCR/ ABL gene (Gorre et al., 2001), and it has been shown that long-term exposure to a suboptimal concentration of STI-571 could lead to the above…”
BackgroundBean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., & Pao, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0151 · Cited by 278
“The T790M mutation occurs at a critical ‘‘gatekeeper’’ residue in the ATP-binding pocket of EGFR, analogous to the T315I mutation in imatinibresistant BCR-ABL (12).”
Maki, R. G., Awan, R. A., Dixon, R. H., Jhanwar, S., & Antonescu, C. R. (2002) · International Journal of Cancer · doi:10.1002/ijc.10535 · Cited by 250
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Intlekofer, A. M., Shih, A. H., Wang, B., Nazir, A., Rustenburg, A. S., Albanese, S. K., Patel, M., Famulare, C., Correa, F. M., Takemoto, N., et al. (2018) · Nature · doi:10.1038/s41586-018-0251-7 · Cited by 281
“The identification of second-site mutations in IDH2 in the setting of acquired resistance to enasidenib therapy raised the possibility of a resistance mechanism similar to those previously reported for BCR-ABL, EGFR, and other tyrosine kinases 13–16 .”
Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., & Sawyers, C. L. (2002) · Blood · doi:10.1182/blood-2002-05-1361 · Cited by 227
Self-citationA novel mechanism underlying drug resistance in chronic epilepsy
Remy, S., Gabriel, S., Urban, B. W., Dietrich, D., Lehmann, T. N., Elger, C. E., Heinemann, U., & Beck, H. (2003) · Annals of Neurology · doi:10.1002/ana.10473 · Cited by 275
“Second, molecular drug targets may undergo a genetic or functional modification after which they are no longer sensitive to their ligands.(6,7) Both of these strategies have been extensively explored in infectious disease, both are utilized by infectious agents as a survival strategy, and knowledge of these mechanisms…”
BackgroundNimmanapalli, R., Fuino, L., Bali, P., Gasparetto, M., Glozak, M. A., Tao, J., Moscinski, L. C., Smith, C. A., Wu, J., Jove, R., et al. (2003) · PubMed · Cited by 303
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 270
“The emergence of a subclone of leukemic cells carrying an imatinib resistance mutation in the BCR-ABL kinase domain lead to disease relapse after treatment with the BCR-ABL kinase inhibitor imatinib [70].”
BackgroundPerspectives on the development of a molecularly targeted agent
Druker, B. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00025-9 · Cited by 273
“No changes in drugs levels have been observed, and leukemic cells from these patients have decreased cellular sensitivity to STI571 (Gorre et al., 2001).”
BackgroundKilling of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)
Wilda, M., Fuchs, U., Wössmann, W., & Borkhardt, A. (2002) · Oncogene · doi:10.1038/sj.onc.1205653 · Cited by 276
“In recent studies, several authors reported the development of resistance to STI 571, e.g. by genomic amplification of BCR/ ABL, increased expression of BCR/ABL mRNA or point mutation in the ABL gene (Mahon et al., 2000; Gorre et al., 2001; Hochhaus et al., 2001; Barthe et al., 2001).”
BackgroundMad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal
Sotillo, R., Schvartzman, J.-M., Socci, N. D., & Benezra, R. (2010) · Nature · doi:10.1038/nature08803 · Cited by 273
Mineo, M., Garfield, S. H., Taverna, S., Flugy, A., De Leo, G., Alessandro, R., & Kohn, E. C. (2012) · Angiogenesis · doi:10.1007/s10456-011-9241-1 · Cited by 268
“However, some patients develop resistance to imatinib due to secondary point mutations in the bcr-abl tyrosine kinase domain or due to BCR-ABL gene amplification [10, 11].”
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Hu, Y., Swerdlow, S., Duffy, T. M., Weinmann, R., Lee, F. Y., & Li, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606509103 · Cited by 271
Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., & Akin, C. (2006) · Blood · doi:10.1182/blood-2005-10-3969 · Cited by 273
Roots of Clinical Resistance to STI-571 Cancer Therapy
Barthe, C., Cony-Makhoul, P., Melo, J. V., & Mahon, J. R. F.-X. (2001) · Science · doi:10.1126/science.293.5538.2163a · Cited by 271
Kobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., & Halmos, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1346 · Cited by 272
“T790M, in the EGFR ATP-binding pocket as a mechanism of secondary resistance to anilinoquinazoline EGFR inhibitors (5, 6). This mutation is analogous to resistance mutations affecting the tyrosine kinase binding domain of imatinib-resistant bcr-abl or c-kit mutations in chronic myeloid leukemia and gastrointestinal st…”
BackgroundImatinib: a selective tyrosine kinase inhibitor
Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T., & Zimmermann, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80599-8 · Cited by 265
Milojkovic, D., & Apperley, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265
Conformational states dynamically populated by a kinase determine its function
Xie, T., Saleh, T., Rossi, P., & Kalodimos, C. G. (2020) · Science · doi:10.1126/science.abc2754 · Cited by 266
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
“The main observed mechanism of resistance to BCR-ABL inhibition is the acquisition of second-site mutations in BCR-ABL itself [26].”
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
“…804 in RET corresponds to threonine 315 in ABL, a residue that is located at a hydrophobic cavity near the nucleotide binding site and that is implicated in resistance to STI571 (Schindler et al., 2000; Gorre et al., 2001; La Rosee et al., 2002; Nagar et al., 2002; Shah et al., 2002) (Figure 5a).”
BackgroundShimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
“threonine-to-methionine amino acid substitution at position 790 (T790M) of EGFR (5, 6), analogous to the T315I mutation that confers resistance of BCR-ABL to imatinib (7, 8).”
BackgroundTyrosine kinase inhibitors: Multi-targeted or single-targeted?
Broekman, F. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i2.80 · Cited by 247
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Aichberger, K. J., Mayerhofer, M., Krauth, M.-T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., et al. (2005) · Blood · doi:10.1182/blood-2004-02-0749 · Cited by 253
Zhao, R., & Goldman, I. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206946 · Cited by 253
“This mechanism of resistance was subsequently shown to be relevant to resistance to other antifolates and other classes of drugs, most recently STI-571 (Gorre et al., 2001).”
BackgroundEvolution of acquired resistance to anti-cancer therapy
Foo, J., & Michor, F. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.02.025 · Cited by 254
“Treatment of chronic myeloid leukemia (CML) with the targeted agent Gleevec (imatinib) fails due to the emergence of point mutations in the BCR-ABL kinase domain (Gorre et al., 2001).”
BackgroundNew Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256
“Several mechanisms have been proposed to underlie the development of imatinib resistance in CML, including BCR-ABL gene mutations (51, 52); overexpression and amplification of the BCR-ABL gene locus (51, 52); activation of BCR-ABL–independent pathways, such as members of the Src kinase family (26); binding of imatinib…”
BackgroundPluk, H., Dorey, K., & Superti-Furga, G. (2002) · Cell · doi:10.1016/s0092-8674(02)00623-2 · Cited by 248
Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., & Van Etten, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162140299 · Cited by 253
Self-citationPfeifer, H., Wassmann, B., Pavlova, A., Wunderle, L., Oldenburg, J., Binckebanck, A., Lange, T., Hochhaus, A., Wystub, S., Brück, P., et al. (2007) · Blood · doi:10.1182/blood-2006-11-052373 · Cited by 249
“Most studies reporting the presence of pretherapeutic KD mutations in CML patients also found them to be present in only a minority of cells comparable with the level we established for Ph ALL,32-35 with the exception of one report in CML that found mutant alleles to represent 40% of the BCR-ABL message.20 It is uncle…”
BackgroundInfluentialMechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia
Quintás-Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer Control · doi:10.1177/107327480901600204 · Cited by 238
Development of novel targeted therapies in the treatment of malignant glioma
Rich, J. N., & Bigner, D. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1380 · Cited by 247
“Cases of chronic myelogenous leukaemia expressing BCR-ABL with resistance to imatinib mesylate are associated with mutation of the ATP-binding site of AB”
BackgroundEide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Waarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 230
Tyner, J. W., Bumm, T. G., Deininger, J., Wood, L., Aichberger, K. J., Loriaux, M. M., Druker, B. J., Burns, C. J., Fantino, E., & Deininger, M. W. (2010) · Blood · doi:10.1182/blood-2009-05-223727 · Cited by 240
Shah, N. P., Kim, D.-W., Kantarjian, H., Rousselot, P., Llacer, P. E. D., Enrico, A., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Muller, M. C., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.011452 · Cited by 244
“Not assessed 52 (32) NA NA 40 (33) NA NA 12 (29) NA NA”
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Ghoreschi, K., Laurence, A., & O'Shea, J. J. (2009) · Nature Immunology · doi:10.1038/ni.1701 · Cited by 241
“Even though imatinib is effective in most patients with CML, leukemic cells can become resistant to imatinib as a result of mutations that render BCR-Abl less sensitive to imatini”
Kimura, S., Naito, H., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara, E., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2209 · Cited by 241
Targeting cancer stem cells to suppress acquired chemotherapy resistance
Vidal, S. J., Rodriguez-Bravo, V, Galsky, M., Cordon-Cardo, C., & Domingo-Domenech, J. (2014) · Oncogene · doi:10.1038/onc.2013.411 · Cited by 242
STI571 (Gleevec™) as a paradigm for cancer therapy
Druker, B. J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02305-5 · Cited by 245
Lack of clinical efficacy of imatinib in metastatic melanoma
Ugurel, S., Hildenbrand, R., Zimpfer, A., La Rosée, P., Paschka, P., Sucker, A., Keikavoussi, P., Becker, J. C., Rittgen, W., Hochhaus, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602529 · Cited by 243
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
Hoover, R. R., Mahon, F.-X., Melo, J. V., & Daley, G. Q. (2002) · Blood · doi:10.1182/blood.v100.3.1068 · Cited by 241
Ba/F3 cells and their use in kinase drug discovery
Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240
Dai, Y., Rahmani, M., Corey, S. J., Dent, P., & Grant, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402290200 · Cited by 239
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
Douer, D., & Tallman, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.217 · Cited by 236
Hofmann, W.-K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., & Koeffler, H. P. (2002) · Blood · doi:10.1182/blood.v99.5.1860 · Cited by 239
Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs
Blagosklonny, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402415 · Cited by 235
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.